Regiochemistry of Isoindolinone Formation in Stachybotrin-Type Alkaloids

Tojiyeva Sevara Namozovna; Xojiyev Jamshid Usmanovich

doi:10.51699/4kkvtj90

Authors

Tojiyeva Sevara Namozovna PhD in Chemical Sciences, Docent of Karshi State University, Karshi, Uzbekistan
Xojiyev Jamshid Usmanovich Lecturer, Asman University, Bukhara, Uzbekistan

DOI:

https://doi.org/10.51699/4kkvtj90

Keywords:

Stachybotrys Chartarum, Phenylspirodrimanes, Stachybotrin, Isoindolinone, Regioselectivity, Semisynthesis, Stachybotrydial

Abstract

Stachybotrin-type alkaloids are usually made rather than isolated. The standard route condenses a primary amine with the ortho-dialdehyde of stachybotrydial, closing the isoindolinone ring in one step. The substrate is unsymmetrical, though, and the ring can close through either aldehyde, so a single amine gives two lactams that differ only in whether C-8 or C-9 carries the carbonyl. For a long time this went unmentioned; products were reported without a regiochemical assignment. Work published in 2024 separated both isomers from tryptophan and tryptamine condensations and assayed them side by side, and the differences are not small. The C-8 isomers were the more cytotoxic against HepG2 and A549 cells, one of them from 2 micromolar upward, while the C-9 isomers were oxidised and glucuronidated faster in hepatic preparations. Within the tryptophan pair the C-9 isomer inhibited factor XIa by 66 per cent against 51 per cent for its partner, so the ranking of activity can invert with constitution alone. The isomer ratio responds to solvent, acid additive, drying agent and the rate at which the amine is delivered, which puts it within preparative reach. This paper reviews that evidence and sets out what a report of such a derivatization needs to contain.

References

[1] X. Ma, M. Wu, Z. Chen, F. Cao, T. Zhong, Z. Luo, Z. Shao, Y. Zhang, L. Chen, and Z. Zhang, “Phenylspirodrimane with moderate reversal effect of multidrug resistance isolated from the deep-sea fungus Stachybotrys sp. 3A00409,” Molecules, vol. 29, no. 7, Art. no. 1685, 2024, doi: 10.3390/molecules29071685.

[2] M. Dayras, E. Sfecci, E. Bovio, O. Rastoin, M. Dufies, F. Fontaine-Vive, E. Taffin-de-Givenchy, T. Lacour, G. Pages, G. C. Varese, and M. Mehiri, “New phenylspirodrimanes from the sponge-associated fungus Stachybotrys chartarum MUT 3308,” Marine Drugs, vol. 21, no. 3, Art. no. 135, 2023, doi: 10.3390/md21030135.

[3] J. Zhao, J. Feng, Z. Tan, J. Liu, J. Zhao, R. Chen, K. Xie, D. Zhang, Y. Li, L. Yu, X. Chen, and J. Dai, “Stachybotrysins A–G, phenylspirodrimane derivatives from the fungus Stachybotrys chartarum,” Journal of Natural Products, vol. 80, no. 6, pp. 1819–1826, 2017, doi: 10.1021/acs.jnatprod.7b00014.

[4] Y. Li, C. Wu, D. Liu, P. Proksch, P. Guo, and W. Lin, “Chartarlactams A–P, phenylspirodrimanes from the sponge-associated fungus Stachybotrys chartarum with antihyperlipidemic activities,” Journal of Natural Products, vol. 77, no. 1, pp. 138–147, 2014, doi: 10.1021/np400824u.

[5] J. W. Kim, S.-K. Ko, H.-M. Kim, G.-H. Kim, S. Son, G. S. Kim, G. J. Hwang, E. S. Jeon, K.-S. Shin, I.-J. Ryoo, Y.-S. Hong, H. Oh, K. H. Lee, N.-K. Soung, D. Hashizume, T. Nogawa, S. Takahashi, B. Y. Kim, H. Osada, J.-H. Jang, and J. S. Ahn, “Stachybotrysin, an osteoclast differentiation inhibitor from the marine-derived fungus Stachybotrys sp. KCB13F013,” Journal of Natural Products, vol. 79, no. 10, pp. 2703–2708, 2016, doi: 10.1021/acs.jnatprod.6b00641.

[6] M. Jacolot, M. Jean, N. Tumma, A. Bondon, S. Chandrasekhar, and P. van de Weghe, “Synthesis of stachybotrin C and all of its stereoisomers: Structure revision,” The Journal of Organic Chemistry, vol. 78, no. 14, pp. 7169–7175, 2013, doi: 10.1021/jo401116r.

[7] A. Jagels, V. Lindemann, S. Ulrich, C. Gottschalk, B. Cramer, F. Hübner, M. Gareis, and H.-U. Humpf, “Exploring secondary metabolite profiles of Stachybotrys spp. by LC-MS/MS,” Toxins, vol. 11, no. 3, Art. no. 133, 2019, doi: 10.3390/toxins11030133.

[8] K. Steinert, N. Berg, D. V. Kalinin, A. Jagels, E.-U. Würthwein, H.-U. Humpf, and S. Kalinina, “Semisynthetic approach toward biologically active derivatives of phenylspirodrimanes from S. chartarum,” ACS Omega, vol. 7, no. 49, pp. 45215–45230, 2022, doi: 10.1021/acsomega.2c05681.

[9] A. Fischle, U. Schreiber, V. Haupt, F. Schimang, L. Schürmann, M. Behrens, F. Hübner, M. Esselen, D. V. Kalinin, and S. A. Kalinina, “Biological evaluation of semi-synthetic isoindolinone isomers produced by Stachybotrys chartarum,” Frontiers in Fungal Biology, vol. 5, Art. no. 1494795, 2024, doi: 10.3389/ffunb.2024.1494795.

[10] Z. Xie, S. Duan, H. Wang, T. Li, and Z. Xie, “Asymmetric total syntheses of ent-stachybotrin C and its congener,” Organic Letters, vol. 26, no. 15, pp. 2918–2922, 2024, doi: 10.1021/acs.orglett.4c00380.

[11] Y. Kuroda, K. Hasegawa, K. Noguchi, K. Chiba, K. Hasumi, and Y. Kitano, “Confirmation of the absolute configuration of stachybotrin C using single-crystal X-ray diffraction analysis of its 4-bromobenzyl ether derivative,” The Journal of Antibiotics, vol. 71, no. 6, pp. 584–591, 2018, doi: 10.1038/s41429-018-0042-2.

[12] D. Augner, D. C. Gerbino, N. Slavov, J.-M. Neudörfl, and H.-G. Schmalz, “N-Capping of primary amines with 2-acyl-benzaldehydes to give isoindolinones,” Organic Letters, vol. 13, no. 19, pp. 5374–5377, 2011, doi: 10.1021/ol202271k.

[13] S. R. M. Ibrahim, H. Choudhry, A. H. Asseri, M. A. Elfaky, S. G. A. Mohamed, G. A. Mohamed, et al., “Stachybotrys chartarum—A hidden treasure: Secondary metabolites, bioactivities, and biotechnological relevance,” Journal of Fungi, vol. 8, no. 5, Art. no. 504, 2022, doi: 10.3390/jof8050504. The review catalogues 215 metabolites reported from S. chartarum and discusses phenylspirodrimanes, trichothecenes, bioactivities, and biosynthetic pathways.

[14] A. Jagels, V. Lindemann, S. Ulrich, C. Gottschalk, B. Cramer, F. Hübner, M. Gareis, and H.-U. Humpf, “Stachybotrys mycotoxins: From culture extracts to dust samples,” Analytical and Bioanalytical Chemistry, 2016, doi: 10.1007/s00216-016-9649-y. The study distinguishes the principal metabolite profiles of different S. chartarum chemotypes and identifies phenylspirodrimanes among the major metabolite groups.

[15] J. Liu, R. Chen, et al., “Complete biosynthesis of phenylspirodrimanes with unclustered genes in Stachybotrys chartarum,” Acta Pharmaceutica Sinica B, vol. 16, no. 2, pp. 966–978, 2026, doi: 10.1016/j.apsb.2025.09.015. The study elucidates the biosynthetic pathway of phenylspirodrimane meroterpenoids using genome mining, gene inactivation, heterologous expression, biochemical experiments, and transcriptomic analysis.